Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: appro who wrote (670)	12/29/1997 3:16:00 PM
From: Czechsinthemail	Respond to of 887

I'm wondering how the revised FDA regulations for off-label use might impact DEPO. If the assumption is correct that the crossbar may be somewhat easier to clear for DepoCyt for leukemia and lymphoma-related NM, could relaxed off-label regs make it possible to expand off-label use for solid tumor and other indications? Also, since this provision is scheduled for 1998, does anyone have any thoughts about how this may affect new drug applications going forward e.g. looking toward the easiest approval rather than the biggest market for a new drug, then adding other indications as off-label uses. Baird